ArticleJournal of the history of biology2025
Asilomar Across the Atlantic: EMBO, EMBL, and the Politics of Scientific Expertise.
Article in Journal of the history of biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shifting Values and Shifting Risks: Debates on the New Biology in Germany and the United States Before and After Asilomar (1960-1980).Journal of the history of biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The internationalization of the 1975 International Asilomar Conference on Recombinant DNA molecules has received little attention, and in particular, the European impact on, and response to, the Asilomar Conference have remained largely unexplored in the historiography to date. This article highlights the role of the European Molecular Biology Organization (EMBO) as a key actor in recombinant DNA research and the issuing of guidelines for recombinant DNA technology on both sides of the Atlantic. It also investigates the legacy of the Asilomar Conference in shaping EMBO's role as a science policy advisor for molecular biology in Europe. Drawing on a wide range of primary sources, the article is divided into three sections. The first section explores EMBO's role as a scientific advisory body in the development and guidance of recombinant DNA research in both the US and Western Europe. The second section investigates the impact of the Asilomar Conference on the European Molecular Biology Laboratory (EMBL) project, reconstructing the scientific and political rationale behind the early construction of a high-risk containment facility in Heidelberg (soon obsolete due to the international relaxation of the guidelines). The third and final section analyzes how, between 1975 and 2004, EMBO reframed the Asilomar legacy as a model for its aspirations to serve as an advisory group for European science policy in molecular biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.